Taltirelin

Drug Profile

Taltirelin

Alternative Names: Ceredist; TA-0910; Taltirelin hydrate

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Tanabe Seiyaku
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Antidementias; Neuropeptides; Neuroprotectants; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Thyrotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Neurological disorders; Spinocerebellar degeneration

Most Recent Events

  • 26 Oct 2009 Oral disintegrating tablet formulation launched for Spinocerebellar degeneration in Japan (PO)
  • 30 Jun 2009 Registered for Spinocerebellar degeneration in Japan (PO)
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top